Mirabilis raises $10.5 million
Therapeutic ultrasound developer Mirabilis Medica of Seattle reported that it has raised $10.5 million in an extension to its series A financing round. The funding will be used to continue developing and testing its image-guided high intensity focused ultrasound (HIFU) system for treatment of gynecological diseases.
Mirabilis’ technology is designed to allow a physician to destroy pathological tissue inside the body without damage to intervening tissue, and to monitor effects with real-time ultrasound imaging. While this approach could address a variety of conditions, Mirabilis said it will initially target its utilization for the treatment of uterine fibroids.
The series A extension was led by Arboretum Ventures of Ann Arbor Mich., and included Split Rock Partners, Dow Venture Capital, and an individual investor, according to the company.
Mirabilis’ technology is designed to allow a physician to destroy pathological tissue inside the body without damage to intervening tissue, and to monitor effects with real-time ultrasound imaging. While this approach could address a variety of conditions, Mirabilis said it will initially target its utilization for the treatment of uterine fibroids.
The series A extension was led by Arboretum Ventures of Ann Arbor Mich., and included Split Rock Partners, Dow Venture Capital, and an individual investor, according to the company.